血液静止剤投与までの時間は,XA因子阻害剤に関連する頭蓋内出血を患った退役軍人の死亡率を増加させる
Nebojsa Markovic1, Emily Budde2, Charlesnika T Evans3
1Department of Veterans Affairs, Edward Hines, Jr. VA Hospital, 5000 South 5th Ave, Hines, IL, USA.
The American journal of emergency medicine
|September 4, 2025
まとめ
Andexanet alfa (AA) と4因子プロトロンビン複合物 (4F- PCC) は,因子XA阻害剤関連出血に対する静止治療の時間差を示さなかった. 薬剤の種類に関係なく,より早い投与は90日間の死亡率の低下と関連しています.
科学分野:
- 心臓病科
- 血液学
- 薬理学について
背景:
- 生命を脅かす出血は,ファクターXA (fXa) 阻害剤を服用している患者で,緊急に血液静止を逆転させる必要があります.
- アンデキサネットアルファ (AA) と4要素プロトロンビン複合濃縮物 (4F-PCC) は,逆転のために使用される主要な薬剤です.
- 2018年に承認されたAAは,優れた有効性を持つ可能性があり,血栓性イベントのリスクがあり,よりコストが高く,4F-PCCの継続的な利用につながります.
研究 の 目的:
- fXa阻害剤の逆転におけるAAと4F-PCCの間の血液静止治療までの時間を比較する.
- 頭蓋内出血 (ICH) の患者の死亡率に対する治療までの時間の影響を評価する.
- これらの薬剤の比較効果と安全性に関する実際のデータを提供すること.
主な方法:
- 2018年1月1日から2024年1月1日までの退役軍人保健局のデータに関する全国的な遡及コホート研究.
- fXa阻害剤関連の出血,主にICHのためにAAまたは4F-PCCを受けた退役軍人246人を含む.
- 主要評価点: 血液静止治療までの時間 二次的エンドポイントは,30日間の血栓性イベントと90日間の死亡率で,診断表のレビューによって検証された.
主要な成果:
- AA群 (203分) と4F-PCC群 (200分) の血液静止治療までの平均時間の有意な差は認められなかった (p=0. 70).
- 全体の90日死亡率は19. 1%でした.
- 血液静止剤の投与までの1分ごとに90日間の死亡率が0. 4%増加した (OR 1. 004,95%CI 1. 001 - 1. 006).
結論:
- fXa阻害剤に関連したICHの退役軍人では,アンデキサネットアルファと4F-PCCは,血液静止治療と同様の期間を示した.
- 治療までの時間は90日間の死亡率に影響を与える重要な要因であり,使用された静止剤とは無関係です.
- 患者の生存率を向上させるため,血液静止剤の投与を加速させる戦略をさらに研究することが可能である.
さらに関連する動画
関連する概念動画
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Anticoagulant Drugs: Low-Molecular-Weight Heparins
888
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
888
Venous Thrombosis IV: Nursing Management
22
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
22
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
42
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
42
Extrinsic and Intrinsic Pathways of Hemostasis
9.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.1K


